Biohit Oyj Stock Exchange Release April 14, 2014 at 10:00 am local time (EET)
The project to validate GastroPanel for Dynex Technologies´ DS2 – ELISA automate has been completed. DS2 operators can now run GastroPanel according to a protocol that has been validated by Biohit. The installed base of DS2 is more than 1,000 units worldwide.
The Dynex automated ELISA systems, will improve the availability and usability of the GastroPanel. With the help of this integrated system solution, small and medium-sized laboratories will be able to perform GastroPanel easily and cost-effectively.
Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com
Dynex Technologies in brief
Dynex (www.dynextechnologies.com) pioneered microplate technology more than 50 years ago, and has since delivered a series of cutting edge, best-of-class processing systems, including the 4-plate DSX and 2-plate DS2 systems, and the newly released Agility 12-plate system. Dynex designs each of its products to meet the rigorous demands of scientists in clinical, biomedical, and pharmaceutical development applications. Dynex is based in Chantilly, Virginia, USA, with locations in Hong Kong, Germany and the UK, and markets its products worldwide.
